Research Analysts Set Expectations for WVE FY2025 Earnings

On March 5, 2025, analysts at HC Wainwright revised their earnings per share (EPS) estimates for Wave Life Sciences Ltd. (NASDAQ:WVE). They have updated their forecast, now projecting that the company will record an EPS of ($0.87) for the fiscal year 2025, a decrease from their earlier estimate of ($0.74). Despite this lowered expectation, HC Wainwright maintains a positive outlook with a "Buy" rating and a target price of $22.00 for the stock.

Presently, the consensus estimate for Wave Life Sciences’ earnings for the full year is ($1.14) per share. Additionally, HC Wainwright has provided earnings projections for upcoming fiscal years, suggesting an EPS of ($1.07) for FY2026, ($0.23) for FY2027, moving to a positive $0.20 for FY2028, and $0.71 for FY2029.

On March 4, 2025, Wave Life Sciences released its quarterly earnings report, which showed earnings of $0.17 per share. This result exceeded the anticipated loss of ($0.17) by a substantial margin of $0.34. The company faced a negative net margin of 66.50% and a notably negative return on equity of 280.57%. Revenue for the quarter reached $83.75 million, significantly surpassing analyst estimates of $25.60 million.

Several other market analysts have also recently weighed in on WVE. StockNews.com upgraded Wave Life Sciences from a "sell" rating to a "hold" rating in a report issued on March 8. Additionally, Truist Financial raised its target price for Wave Life Sciences from $17.00 to $36.00, affirming a "buy" rating on November 12. On February 25, Jefferies Financial Group began coverage on Wave Life Sciences, assigning a "buy" rating with a price target of $26.00. Mizuho also increased their price target for the company from $19.00 to $22.00, giving it an "outperform" rating in a report released on November 21. Currently, the stock has received ratings where two analysts suggest holding, eight recommend buying, and one gives a strong buy, leading to an overall consensus rating of "Moderate Buy" with an average price target of $22.60.

Wave Life Sciences Stock Overview

As of Friday, Wave Life Sciences stock (NASDAQ: WVE) opened at $9.40. Over the past year, it has seen a low of $4.25 and a high of $16.74. The company's market capitalization stands at $1.44 billion with a price-to-earnings ratio of -8.47. The stock's beta is recorded at -1.04, indicating a less volatile performance compared to the market.

Insider Transactions

In recent insider trading news, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences on March 7, at an average price of $9.57 per share. This sale brought in a total of approximately $1.62 million. Following this transaction, the CEO holds 338,351 shares, worth about $3.24 million. This action represents a 33.31% reduction in his holding. The sale was disclosed in a filing with the SEC, and currently, corporate insiders own 29.10% of the company's stock.

Institutional Holdings

Numerous institutional investors have made adjustments to their holdings in Wave Life Sciences recently. GF Fund Management CO. LTD. entered a new position in the company during the fourth quarter, valued around $40,000. Similarly, Quarry LP purchased a new stake worth approximately $62,000 during the same period. KBC Group NV also acquired a new position worth about $67,000. Summit Investment Advisors Inc. increased their holding in WVE by 31.5% during the fourth quarter, now owning a total of 9,642 shares after adding 2,308 shares in the last quarter. Westwood Wealth Management also bought into Wave Life Sciences, acquiring shares worth roughly $124,000. Overall, institutional ownership stands at about 89.73%.

Company Overview

Wave Life Sciences Ltd. is a clinical-stage biotechnology firm that focuses on designing, developing, and commercializing ribonucleic acid (RNA) medicines through its proprietary platform, PRISM. This innovative approach integrates multiple modalities, chemistry innovations, and a deep understanding of human genetics to achieve groundbreaking advancements in treating both rare and more common disorders.

WVE, earnings, analysts